Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Amortizatization of Intangibles: 2017-2025

Historic Amortizatization of Intangibles for Denali Therapeutics (DNLI) over the last 7 years, with Sep 2025 value amounting to $900,000.

  • Denali Therapeutics' Amortizatization of Intangibles rose 125.00% to $900,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 83.65%. This contributed to the annual value of $1.2 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Denali Therapeutics reported Amortizatization of Intangibles of $900,000 as of Q3 2025, which was down 0.00% from $900,000 recorded in Q2 2025.
  • Denali Therapeutics' 5-year Amortizatization of Intangibles high stood at $11.5 million for Q2 2023, and its period low was -$2.7 million during Q3 2021.
  • For the 3-year period, Denali Therapeutics' Amortizatization of Intangibles averaged around $3.3 million, with its median value being $900,000 (2025).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first slumped by 5,528.57% in 2021, then surged by 2,448.88% in 2023.
  • Denali Therapeutics' Amortizatization of Intangibles (Quarterly) stood at -$2.4 million in 2021, then soared by 158.80% to $1.4 million in 2022, then soared by 2,448.88% to $11.5 million in 2023, then reached $769,000 in 2024, then soared by 125.00% to $900,000 in 2025.
  • Its Amortizatization of Intangibles was $900,000 in Q3 2025, compared to $900,000 in Q2 2025 and $900,000 in Q1 2025.